Cargando…
Use of glucagon‐like peptide‐1 receptor agonists among individuals on basal insulin requiring treatment intensification
As Type 2 diabetes progresses, treatment is intensified with additional therapies in an effort to manage hyperglycaemia effectively and therefore avoid complications. When greater efficacy is required, options for injectable treatments include glucagon‐like peptide‐1 receptor agonists and insulin, w...
Autores principales: | Trautmann, M. E., Vora, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5969085/ https://www.ncbi.nlm.nih.gov/pubmed/29478255 http://dx.doi.org/10.1111/dme.13610 |
Ejemplares similares
-
Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short‐acting and other glucagon‐like peptide‐1 receptor agonists
por: Giorgino, Francesco, et al.
Publicado: (2016) -
Impact of delaying treatment intensification with a glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database
por: Tong, Liyue, et al.
Publicado: (2017) -
Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes
por: Nomoto, Hiroshi
Publicado: (2023) -
Transitioning from basal–bolus or premix insulin therapy to a combination of basal insulin and glucagon‐like peptide‐1 receptor agonist in people with type 2 diabetes
por: Mehta, Roopa, et al.
Publicado: (2022) -
Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study
por: Takeshita, Yumie, et al.
Publicado: (2022)